Human immunodeficiency virus type 2 (HIV-2) infection was first described in 1985 in West Africa (2) . Since then, infection with HIV-2 is well recognized in West Africa and now is increasingly being identified in other parts of the world. Therefore, differential serodiagnosis of HIV-2 infection from HIV-1 infection, which has caused a worldwide epidemic, is urgently required.
However, sera from approximately 80% of HIV-2-infected patients are reactive for HIV-1 in enzyme-linked immunosorbent assays and are also cross-reactive on Western blots (immunoblots), depending on the specific kit used (4, 9) . Diagnosis is made more complicated by reports of dual infection with HIV-1 and HIV-2 in individual patients (11, 12) . In Japan, a total of 3,247 cases of HIV infection were reported to the Ministry of Health and Welfare by the end of February 1994. Of these, none were identified as being HIV-2. However, some samples of sera from HIV-1-infected patients showed a serological cross-reaction with HIV-2, causing confusion in the diagnosis. The interpretation of dually seroreactive HIV-1 and HIV-2 blood samples is a serious problem that must be solved (5) . Therefore, we tried to clarify whether such dual seroreactivity is due to true mixed infection with HIV-1 and HIV-2 or HIV-1 infection with a strong cross-reaction with HIV-2 antigens. The results were compared with sera from West African patients considered to have mixed infections with HIV-1 and HIV-2.
MATERIALS AND METHODS
Sera from 66 HIV-infected Japanese patients, 28 with high-risk behaviors and 38 with hemophilia, were used in the study. Sera from three patients supposedly with mixed HIV-1 and HIV-2 infections obtained from West Africa were also examined. As controls, three serum samples which were solely reactive with HIV-2 (serum samples B1, B2, and B3) purchased from Boston Biomedic Inc., and three serum samples from Japanese subjects which were solely reactive with HIV-1 (serum samples A1, A2, and A3) were used.
Gelatin particle agglutination (PA) (13) for HIV-1 and HIV-2 (Fuji Rebio) was used for primary screening. The PA pattern was determined after mixing equal volumes of 1% gelatin particles (GPs) coated with HIV-1 antigen (GP-HIV-1) or HIV-2 antigen (GP-HIV-2) and serially diluted serum samples on a microplate. Patients with a PA titer of greater than 1:16 for HIV-1 PA and those with a PA titer of greater than 1:32 for HIV-2 PA by repeated titration were considered seropositive. More than two bands detected by the Western blot test for HIV-1 or HIV-2 (New LAV BLOT 1 or LAV BLOT 2) were considered to indicate positivity and one band was considered an indeterminate result, according to the manufacturer's (Diagnostic Pasteur) criteria.
Serum samples reactive to synthetic GP-41 (for HIV-1) are classified as PEPTI-LAV-1 seropositive, and those reactive to synthetic GP-36 (for HIV-2) are classified as PEPTI-LAV-2 seropositive according to the manufacturer's (Diagnostic Pasteur) criteria.
The cross-absorption test was carried out as follows. A total of 500 l of 1% GP-HIV-1 or GP-HIV-2 was spun down in each microtube, and the supernatants were removed. A total of 10 l of serum diluted 1/100 was mixed well with GP-HIV-1 or GP-HIV-2 deposited in the tube, and the mixture was incubated for 30 min at room temperature for absorption. This procedure was repeated three times. After centrifugation, 5 l of serially diluted sera was mixed with 5 l of 1% GP-HIV-1 or GP-HIV-2 reagents in a Terasaki plate. After complete mixing with agitation and 30 min of incubation at room temperature, the agglutination pattern was read (10) .
PCR tests for detection of the progenomes of HIV-1 and HIV-2 were carried out by using primers specific for HIV-1 (8) and HIV-2 (1, 3) by nested double PCR. As positive controls for proviral HIV-1, strain NY-10-infected cells were used (7), and for proviral HIV-2, strain GH-1-infected cells were used.
RESULTS
Sixty-six serum samples obtained from HIV-1-infected patients in Japan were positive for HIV-1 PA with titers of greater than 10,000. They showed more than two bands by LAV BLOT 1. These were tested for HIV-2 PA reactivity. Twenty serum samples were positive, with HIV-2 PA titers of greater than 32. Of these, two were positive at titers of 1:1,000 and two others were positive at titers 1:10,000. Of the former two, one showed more than two bands (positive) and the other showed one band (indeterminate) by LAV BLOT 2. These two serum samples were negative by PEPTI-LAV-2. The two samples with HIV-2 PA titers of greater than 1:10,000 were posi-tive for LAV BLOT 2 and were positive by PEPTI-LAV-2 and PEPTI-LAV-1 as well. For these two serum samples (serum samples J1 and J2), it is difficult to determine whether the results were due to mixed infections with HIV-1 and HIV-2 or HIV-1 infection with a strong cross-reaction with HIV-2 antigens.
Three control serum samples from West Africa (serum samples W1, W2, and W3) that were supposed to be infected with both HIV-1 and HIV-2 showed high titers by both HIV-1 PA and HIV-2 PA. They were all positive by HIV-1 and HIV-2 Western blot tests and by HIV-1 and HIV-2 PEPTI-LAV tests. Those three control serum samples known to be solely reactive with HIV-2 (serum samples B1, B2, and B3) were positive for HIV-2 by PA, Western blotting, and PEPTI-LAV and were negative for HIV-1.
Then, we analyzed these serum samples by PCR to identify HIV-1 genomes or HIV-2 genomes in blood leukocytes.
In serum samples J1 and J2 from Japan, only the HIV-1 genome was identified in the tested material. Leukocytes of West African serum samples W1 to W3 were not stored under conditions that preserved viral genomes, and we could not detect either proviral HIV-1 or proviral HIV-2.
Cross-absorption tests with HIV-1 and HIV-2 antigens were carried out with serum samples J1 and J2 and serum samples W1 to W3, with the result being strong dual seroreactivity to HIV-1 and HIV-2. In serum samples J1 and J2, after absorption of the HIV-1 antigen, the reactivities of both HIV-1 PA and HIV-2 PA were absorbed out. In contrast, HIV-2 antigen absorbed out HIV-2 PA reactivity only but not HIV-1 PA reactivity. In West African serum samples W1 to W3, the HIV-1 antigen absorbed only HIV-1 PA reactivity but did not absorb HIV-2 PA reactivity. The HIV-2 antigen also absorbed only HIV-2 PA reactivity but not HIV-1 PA reactivity. Both sets of control sera showed the expected results: the HIV-1 PA reactivities of serum samples A1 to A3 were absorbed out with HIV-1 antigen, and the HIV-2 PA reactivity of the HIV-2-infected panel of sera from Boston Biomedic Inc. (serum samples B1 to B3) was absorbed out with HIV-2 antigen (Table 1) .
On the basis of the PCR and cross-absorption results presented above, we can conclude that the seroreactivities of serum samples J1 and J2 were due to HIV-1 infection with cross-reactivity, even though cross-reaction with HIV-2 antigen occurred in Western blot and PEPTI-LAV tests (Table 2) . In contrast, the West African serum samples showed a true serological mixed infection pattern with HIV-1 and HIV-2.
DISCUSSION
Dual serological reactivities to HIV-1 and HIV-2 are common in areas where both HIV-1 and HIV-2 occur, and one should not overestimate the prevalence of mixed infection on the basis of serological tests. Screening by PA in Japan showed that even when HIV-2 infection has not been found, serological dual reactivity with HIV-2 was observed in 20 of 66 HIV-1-positive serum samples. In test serum samples with high-titer HIV-2 PA reactivity, neither Western blotting nor the PEPTI-LAV test could differentiate HIV-1 infection with cross-reactivity with HIV-2 from a real mixed infection, as observed in the serum samples from West Africa. Our serological crossabsorption test can differentiate these cases and confirm the results of specific PCR tests.
As for the two serum samples from Japan (serum samples J1 and J2), PCR results showed that they were likely infected with HIV-1, with serological cross-reactivity with HIV-2 antigen. However, a possibility of exposure to both viruses cannot be excluded; even though the HIV-2 genome was not detected in the sample with specific primers, the virus might exist elsewhere in the body. Although the PCR technique itself is highly sensitive and specific, its dependence on technological amplification in vitro makes sample size an important limitation. On the other hand, a specific antibody response against infecting viruses is the result of biological amplification of infection in vivo, which can be monitored serologically by using small, handy volumes of serum in vitro. Our proposed serological cross-absorption test is based on biological amplification, and when it is used together with the PCR test based on in vitro amplification, it proved to be highly specific and useful for differential diagnosis. Moreover, a highly specific serological method for the differentiation of HIV-1 or HIV-2 infections, such as our cross-absorption test, would contribute to the identification of the type of infecting viruses, especially in cases in which patient serum samples were not stored under conditions that would preserve viral genomes, as often occurred in the study of samples from the field, such as the serum samples from West Africa in our study. Such a method could also be used for samples from infected hosts who have a very limited quantity of virus and for whom the type of infecting virus can be identified only by detectable antibodies.
